This Core Grant support is for administration, laboratory head's salaries, central office, glassware washing and animal facility personnel, central GCDC operation functions, tissue culture media preparation, electron microscopy and histopathology central functions, synthetic chemistry central resource, shared instrument, biomathematical resource, development of new laboratory units and initial support of pilot studies. The scientific functions of the GCDC are related to: 1) the development of study of new drugs originating in the medicinal chemistry groups of the Center or obtained from the outside; 2) the study of basic aspects of cell metabolism and biology that may lead to the development of new compounds and treatments, with emphasis on (a) regulation of normal and neoplastic cell metabolism, (b) alterations leading to neoplastic processes and cell transformation, (c) role of the plasma membrane, and (d) selectivity of immunomodulation by drugs and tumors; 3) the preclinical study of the biochemical and pharmacological basis for the selectivity of anticancer drugs and treatments, with emphasis on the acquisition and integration of information leading towards the identification of means to increase the selectivity of drug action against tumors; 4) the study, in close cooperation with clinical deparments, of the pharmacological and biochemical determinants of drug action in humans with emphasis on (a) development of new drugs, (b) clarification of the mode of action of known drugs, (c) development of new treatments through the identification of the pharmacological and biochemical determinants of tumor sensitivity in individual patients, and (d) determination of biochemical characteristics of different types of cancer or of different stages of disease.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Cancer Center Support Grant Review Committee (CCS)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Klaich, G M; Kanter, P M (1995) Characterization of a monoclonal antibody recognizing a 138 kDa glioblastoma-associated antigen. Anticancer Drugs 6:45-52
Verstovsek, S; Eppolito, C; Ujhazy, P et al. (1995) Murine splenic macrophage tumoricidal activation by cytokines. Exp Hematol 23:519-28
Ujhazy, P; Maccubbin, D; Eppolito, C et al. (1994) TNF-alpha potentiation of the lymphokine-activated killer response of murine thymus cells. Lymphokine Cytokine Res 13:99-106
Klaich, G M; Kanter, P M (1994) Induction of dog IL-1 by free and liposomal encapsulated doxorubicin. Anticancer Drugs 5:355-60
Ujhazy, P; Klobusicka, M; Babusikova, O et al. (1994) Ecto-5'-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin. Int J Cancer 59:83-93
Kanter, P M; Klaich, G; Bullard, G A et al. (1994) Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99) given intraperitoneally to dogs. In Vivo 8:975-82
Kanter, P M; Bullard, G A; King, J M (1994) Preclinical toxicologic evaluation of DENSPM (N1,N11-diethylnorspermine) in rats and dogs. Anticancer Drugs 5:448-56
Kanter, P M; Klaich, G M; Bullard, G A et al. (1994) Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 5:579-90
Sufrin, J R; Lombardini, J B; Alks, V (1993) Differential kinetic properties of L-2-amino-4-methylthio-cis-but-3-enoic acid, a methionine analog inhibitor of S-adenosylmethionine synthetase. Biochim Biophys Acta 1202:87-91
Ho, R L; Maccubbin, D L; Ujhazy, P et al. (1993) Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma. Oncol Res 5:363-72

Showing the most recent 10 out of 149 publications